Yayın: Pembrolizumab in relapsed or refractory Richter syndrome
| dc.contributor.author | Philippe Armand | |
| dc.contributor.author | Gülbaş, Zafer | |
| dc.contributor.author | Niels Murawski | |
| dc.contributor.author | Daniel Molin | |
| dc.contributor.author | Jasmine Zain | |
| dc.contributor.author | Barbara Eichhorst | |
| dc.contributor.author | Zafer Gülbaş | |
| dc.contributor.author | Eliza A. Hawkes | |
| dc.contributor.author | John M. Pagel | |
| dc.contributor.author | Tycel Phillips | |
| dc.contributor.author | Vincent Ribrag | |
| dc.contributor.author | Jakub Svoboda | |
| dc.contributor.author | Anastasios Stathis | |
| dc.contributor.author | Arkendu Chatterjee | |
| dc.contributor.author | Robert Orlowski | |
| dc.contributor.author | Patricia Marinello | |
| dc.contributor.author | Beth Christian | |
| dc.contributor.orcid | 0000-0001-6098-1603 | |
| dc.contributor.orcid | 0009-0005-6662-4865 | |
| dc.contributor.orcid | 0009-0009-0753-1019 | |
| dc.contributor.orcid | 0000-0001-9990-6918 | |
| dc.contributor.orcid | 0000-0002-4709-0627 | |
| dc.contributor.orcid | 0000-0002-0376-2559 | |
| dc.contributor.orcid | 0000-0001-5745-8125 | |
| dc.contributor.orcid | 0000-0003-2143-9672 | |
| dc.contributor.orcid | 0000-0002-5221-353X | |
| dc.contributor.orcid | 0000-0002-6359-7065 | |
| dc.contributor.orcid | 0000-0002-2859-7529 | |
| dc.contributor.orcid | 0000-0001-7884-6928 | |
| dc.contributor.orcid | 0000-0002-8037-9932 | |
| dc.date.accessioned | 2025-11-13T09:31:36Z | |
| dc.date.issued | 2020-06-16 | |
| dc.identifier.doi | https://doi.org/10.1111/bjh.16762 | |
| dc.identifier.endpage | e120 | |
| dc.identifier.issn | 0007-1048 | |
| dc.identifier.issue | 2 | |
| dc.identifier.openalex | W3034529667 | |
| dc.identifier.startpage | e117 | |
| dc.identifier.uri | https://hdl.handle.net/11421/1395 | |
| dc.identifier.uri | https://doi.org/10.1111/bjh.16762 | |
| dc.identifier.volume | 190 | |
| dc.language.iso | en | |
| dc.relation.ispartof | British Journal of Haematology | |
| dc.rights | openAccess | |
| dc.subject | Medicine | |
| dc.subject | Pembrolizumab | |
| dc.subject | Internal medicine | |
| dc.subject | Rituximab | |
| dc.subject | Oncology | |
| dc.subject | Lymphoma | |
| dc.subject | Chemotherapy | |
| dc.subject | Refractory (planetary science) | |
| dc.subject | Transplantation | |
| dc.subject | Aggressive lymphoma | |
| dc.subject | Immunotherapy | |
| dc.subject | Cancer | |
| dc.subject.sdg | 3 | |
| dc.title | Pembrolizumab in relapsed or refractory Richter syndrome | |
| dc.type | letter | |
| dspace.entity.type | Publication | |
| local.authorid.openalex | A5058571002 |
